Phase II Trial of the CDK4 Inhibitor PD0332991 in Patients With Advanced CDK4-Amplified Well-Differentiated or Dedifferentiated Liposarcoma

The Cyclin-Dependent Kinase Inhibitor Flavopiridol Potentiates Doxorubicin Efficacy in Advanced Sarcomas: Preclinical Investigations and Results of a Phase I Dose-Escalation Clinical Trial

(2012) J. J. Luke et al.   CLINICAL CANCER RESEARCH

Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)

(2011) G K Schwartz et al.   BRITISH JOURNAL OF CANCER

Clinical and molecular approaches to well differentiated and dedifferentiated liposarcoma

(2011) Aimee M Crago et al.   CURRENT OPINION IN ONCOLOGY

The CDKN2A/CDKN2B/CDK4/CCND1 pathway is pivotal in well-differentiated and dedifferentiated liposarcoma oncogenesis. An analysis of 104 tumors

(2011) Caroline Louis-Brennetot et al.   GENES CHROMOSOMES & CANCER

Testing new regimens in patients with advanced soft tissue sarcoma: analysis of publications from the last 10 years

(2010) N. Penel et al.   ANNALS OF ONCOLOGY

Evaluation of well-differentiated/de-differentiated liposarcomas by high-resolution oligonucleotide array-based comparative genomic hybridization

(2010) William D. Tap et al.   GENES CHROMOSOMES & CANCER

Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy

(2010) Jordi Barretina et al.   NATURE GENETICS

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER